Insider · CIK 0001496687

Machiels Alec

Reports to the SEC for 3 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001496687

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	Director	UDisposition from Tender	−385K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	Director	UDisposition from Tender	−250K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	Director	UDisposition from Tender	−12K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	Director	UDisposition from Tender	−150K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−3,062 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−5,744 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−7,961 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−3,544 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17.6K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−122K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−14.7K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.6K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−11.2K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−8,554 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−7,441 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.6K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,748 sh	—	—	0
2026-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+7,961 sh	—	—	384,989
2026-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.7K sh	—	—	14,684
2025-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+6,267 sh	—	—	377,028
2025-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+11.2K sh	—	—	11,199
2024-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+3,341 sh	—	—	370,761
2024-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,748 sh	$59.86	+$344K	5,748
2023-11-17	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	368,670
2023-11-17	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$47.74	−$59.7K	367,420
2023-11-17	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,250 sh	—	—	0
2023-10-17	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	368,670
2023-10-17	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$48.50	−$60.6K	367,420
2023-10-17	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,250 sh	—	—	1,250
2023-09-18	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	368,670
2023-09-18	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$45.00	−$56.3K	367,420
2023-09-18	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,250 sh	—	—	2,500
2023-09-15	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	368,670
2023-09-15	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$45.34	−$56.7K	367,420
2023-09-15	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,250 sh	—	—	3,750
2023-07-21	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+49.8K sh	$2.67	+$133K	367,420
2023-07-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−49.8K sh	—	—	5,000
2023-07-20	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+50K sh	$2.67	+$134K	317,641
2023-07-20	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−50K sh	—	—	54,779
2023-07-17	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	268,891
2023-07-17	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$64.79	−$81K	267,641
2023-07-17	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,250 sh	—	—	104,779
2023-06-20	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	268,891
2023-06-20	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$88.41	−$111K	267,641
2023-06-20	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,250 sh	—	—	106,029
2023-05-17	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	268,891
2023-05-17	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$88.66	−$111K	267,641
2023-05-17	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,250 sh	—	—	107,279
2023-04-17	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,250 sh	$2.67	+$3,337.5	268,891
2023-04-17	APLSApellis Pharmaceuticals, Inc.S Sale	Director	SSale	−1,250 sh	$81.05	−$101K	267,641

Recent filings

Accepted (ET)
May 144
Machiels Alec0001193125-26-224611
SEC(opens sec.gov)
Jan 54
Machiels Alec0001492422-26-000014
SEC(opens sec.gov)
Jan 34
Machiels Alec0001127602-25-000436
SEC(opens sec.gov)

Companies

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451